Literature DB >> 7605960

[MR mammography at 0.5 tesla. II. The capacity to differentiate malignant and benign lesions in MR mammography at 0.5 and 1.5 T].

C K Kuhl1, B P Kreft, A Hauswirth, J Gieseke, A Elevelt, M Reiser, H H Schild.   

Abstract

PURPOSE: To determine whether medium field strength (0.5 T) MR mammography is able to differentiate between benign and malignant lesions in the same way as a 1.5 T standard technique. MATERIAL: In 40 consecutive female patients with nodular lesions, examinations were carried out at 1.5 T (2D-FFE, TR/TE/FA 200/3.9/80) and 0.5 T (3D-FFE, 24/3.4/40).
RESULTS: There was wide spread of the speed of enhancement of malignant tumours for both techniques (44%-145% with signal increase in the first minute of 42%-189%). In 15 out of 17 carcinomas, the rapidity of uptake and final degree of enhancement after contrast was higher during 0.5 T/3D measurements than it was for 1.5 T/2D images. Fibroadenomas and mastopathies showed similar enhancement characteristics for both techniques. Sharply defined "wash-out" was seen only in malignant lesions; it appeared ten times more frequently in the 0.5 T/3D examinations than at 1.5 T/2D.
CONCLUSIONS: The distinction between benign and malignant lesions can be made with more certainty using medium field strength and 3D-FFE sequence than using the 2D high-field standard technique.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7605960     DOI: 10.1055/s-2007-1015922

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  2 in total

1.  Prospective screening study of 0.5 Tesla dedicated magnetic resonance imaging for the detection of breast cancer in young, high-risk women.

Authors:  Wendy S Rubinstein; Jean J Latimer; Jules H Sumkin; Michelle Huerbin; Stephen G Grant; Victor G Vogel
Journal:  BMC Womens Health       Date:  2006-06-26       Impact factor: 2.809

Review 2.  The Changing World of Breast Cancer: A Radiologist's Perspective.

Authors:  Christiane K Kuhl
Journal:  Invest Radiol       Date:  2015-09       Impact factor: 6.016

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.